Skip to main content
. Author manuscript; available in PMC: 2023 Jul 7.
Published in final edited form as: Mol Cell. 2022 May 9;82(13):2472–2489.e8. doi: 10.1016/j.molcel.2022.04.015

Figure 6. KDM2A inhibition restores sensitivity of NSD1-depleted cells to EZH2 inhibition.

Figure 6.

(A) Clonogenic assay results from EZH2 and KDM2A inhibition of G401 control and NSD1 depleted cells treated for 14 days. Human fibroblasts (HFF-1) and HEK293T cells served as controls. Each experiment was performed with n=2 biological replicates and n=3 technical replicates and scanned by densitometry.

(B) TT-based proliferation curves of G401 control or NSD1 depleted cells treated with either DMSO, EZH2i (GSK126) 1uM, KDM2Ai (TC-E5002) 10uM or a combination (n=3 biological replicates).

(C) Incucyte-based proliferation curves of G401 control and NSD1 depleted cells expressing either shCTRL or shKDM2A and treated with DMSO, EZH2i (GSK126) 1uM, KDM2Ai (TC-E5002) 10uM or a combination. Two-way Anova with Turkey’s test for multiple hypothesis correction. Error bars represent means ±s.d. (n=3 biological replicates). *p < 0.05; **p < 0.01; ***p < 0.001.

(D) Immunoblot analysis of G401, HFF-1 and HEK293T cells treated with a combination of 1uM GSK126 and 10uM TC-E5002 or with KDM2A shRNA, after 7 days of treatment. Representative blots are shown from n=2 biological replicates.